Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Free Cash Flow (2016 - 2025)

Moleculin Biotech's Free Cash Flow history spans 10 years, with the latest figure at -$5.4 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$5.4 million for Q4 2025, down 5.57% from a year ago — trailing twelve months through Dec 2025 was -$22.7 million (up 4.77% YoY), and the annual figure for FY2025 was -$22.7 million, up 4.77%.
  • Free Cash Flow for Q4 2025 was -$5.4 million at Moleculin Biotech, up from -$7.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.6 million in Q1 2021 to a low of -$8.1 million in Q2 2022.
  • The 5-year median for Free Cash Flow is -$5.8 million (2024), against an average of -$5.9 million.
  • The sharpest move saw Free Cash Flow plummeted 76.21% in 2022, then soared 36.27% in 2023.
  • Year by year, Free Cash Flow stood at -$4.3 million in 2021, then plummeted by 69.93% to -$7.3 million in 2022, then surged by 31.39% to -$5.0 million in 2023, then dropped by 2.11% to -$5.1 million in 2024, then dropped by 5.57% to -$5.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$5.4 million, -$7.2 million, and -$5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.